



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Ellen W. Evans

Application No.: 10/673,888

Filed: 09/29/2003

For: Methods for Treating Disorders of Calcium Homeostasis

Group Art Unit: 1623

Examiner: Roy P. Issac

Atty. Docket No. : OC01600 US

X

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Mail Stop: Amendment  
Sir:

(a) Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the documents listed on the accompanying Forms PTO/SB/08a & 08b be considered and made of record in the above-identified patent application. Other than cited U.S. patents and published patent applications, copy(ies) of these documents ☒ are enclosed ☐ were filed in related U.S. Application No(s) \_\_\_\_\_ filed \_\_\_\_\_ respectively. Since the Examiner is believed to have ready access to the cited U.S. patents and published patent applications, copies of these documents are not herewith transmitted, but will be provided upon request.

(b) No fee is believed to be due because:

- ☐ This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); **or**
- ☐ This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c) ☒ This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **or**
- ☒ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- (d) ☐ This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and:
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **and**
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365.


The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case.


Dated: 01/17/2007

**Schering-Plough Corporation**  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388

Respectfully submitted,

By:

  
THOMAS A. TRIOLO  
Reg. No.: 48,001  
**Agent of Record**  
Telephone No.: 908-298-2347



Approved for use through 07/31/2006. OMB No. 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: OC01600 US	SERIAL NO.: 10/673,888
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE AS MANY SHEETS AS NECESSARY)		APPLICANT: Evans <i>et al.</i>	
		FILING DATE: Sept. 29, 2003	GROUP: 1623
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	FISHER <i>et al.</i> , Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):133-8.	
	AB	DUNFORD <i>et al.</i> , Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.	
	AC	OLGAARD <i>et al.</i> , Prevention of uremic bone disease using calcimimetic compounds, Annu Rev Med. 2001;52:203-20.	
	AD	FOX <i>et al.</i> , Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats, J Pharmacol Exp Ther. 1999 Aug;290(2):480-6.	
	AE	CHATTOPADHYAY <i>et al.</i> , Cellular "sensing" of extracellular calcium (Ca(2+)(o)): emerging roles in regulating diverse physiological functions, : Cell Signal. 2000 Jun;12(6):361-6.	
	AF	COBURN <i>et al.</i> , Calcium-sensing receptor and calcimimetic agents. Kidney Int Suppl. 1999 Dec;73:S52-8.	
	AG	CANALIS, Novel treatments for osteoporosis, J Clin Invest. 2000 Jul;106(2):177-9.	
	AH	GOODMAN <i>et al.</i> , The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism, J Am Soc Nephrol. 2002 Apr;13(4):1017-24.	
	AI	NEMETH <i>et al.</i> , Calcimimetics with potent and selective activity on the parathyroid calcium receptor, Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4040-5.	
	AJ	COHEN <i>et al.</i> , Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics, Biochem Pharmacol. 2000 Oct 15;60(8):1061-8.	
Examiner signature:		Date considered:	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.